Amide Tech

Executive Summary

Amide Tech is a San Diego-based biotechnology company that has developed an Automated Fast Flow Peptide Synthesis (AFPS) platform for the rapid, on-demand production of complex and long peptides, including those with unnatural amino acids, branched structures, and mirror-image proteins. Founded in 2015, the company addresses a critical bottleneck in drug discovery by enabling researchers to access hard-to-source peptides that are often difficult to synthesize using conventional methods. The AFPS platform accelerates the iterative design-test cycle, potentially reducing the time required to generate novel peptide-based therapeutics or research tools. Despite being a private company with no disclosed funding or revenue, its niche focus on complex peptide synthesis positions it as a valuable partner for pharmaceutical and biotechnology firms seeking to expand their peptide pipelines. Amide Tech operates in the growing peptide therapeutics market, which is driven by the increasing recognition of peptides as effective modulators of protein-protein interactions and intracellular targets. The company's ability to produce mirror-image proteins and other non-standard peptides could open up new applications in areas such as oncology, metabolic disorders, and infectious diseases. While the company remains early-stage, its proprietary synthesis technology and service-oriented business model may attract strategic partnerships or venture capital investment to scale operations. Future catalysts include potential collaborations with big pharma, completion of a Series A financing round, or the demonstration of a breakthrough synthesis milestone that validates the platform's superior capabilities.

Upcoming Catalysts (preview)

• Q4 2026Securing a major pharmaceutical partnership for peptide supply40% success
• Q1 2027Closing a Series A funding round50% success
• Q3 2026Demonstration of novel mirror-image protein synthesis capability60% success